Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Frequency Therapeutics, Inc. (FREQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Termination of a Material Definitive Agreement, Other Events  Interactive Data
08/15/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/10/2023 8-K Quarterly results
Docs: "Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results"
07/31/2023 8-K Quarterly results
07/14/2023 8-K Quarterly results
07/14/2023 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Korro Bio and Frequency Therapeutics Announce Merger Agreement",
"Investor Presentation dated July 2023"
06/06/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "Amendment to Letter Agreement by and between Frequency Therapeutics, Inc. and Richard Mitrano"
03/29/2023 8-K Quarterly results
03/10/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results"
02/13/2023 8-K Quarterly results
12/13/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
09/12/2022 8-K Investor presentation
Docs: "Frequency Therapeutics, Inc. Corporate Slide Presentation as of September 12, 2022",
"Frequency Therapeutics, Inc. Corporate Slide Presentation as of September 12, 2022"
08/09/2022 8-K Quarterly results
Docs: "Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results Q1 2023 Readout Planned for FX-322-208 Phase 2b Sensorineural Hearing Loss Study, with Enrollment Completion Anticipated in Q3 Q4 Enrollment Start Planned for Phase 1b Study of Second Hearing Restoration Program, FX-345 Company Advances Remyelination in Multiple Sclerosis Program, Remains on Pace for 2023 Clinical Start"
07/12/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
04/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Letter Agreement, by and between Frequency Therapeutics, Inc. and Richard Mitrano",
"Letter Agreement, by and between Frequency Therapeutics, Inc. and Wendy Arnold"
04/08/2022 8-K Investor presentation
Docs: "Frequency Therapeutics, Inc. Corporate Slide Presentation as of April 8, 2022",
"Frequency Therapeutics, Inc. Corporate Slide Presentation as of April 8, 2022"
03/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement, by and between Frequency Therapeutics, Inc. and Peter P. Pfreundschuh",
"Separation Agreement, by and between Frequency Therapeutics, Inc. and Peter P. Pfreundschuh"
03/18/2022 8-K Investor presentation
Docs: "Frequency Therapeutics, Inc. Corporate Slide Presentation as of March 18, 2022",
"Frequency Therapeutics, Inc. Corporate Slide Presentation as of March 18, 2022"
03/15/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results Company Reports Steady Enrollment for FX-322-208 Phase 2b Study in Individuals with Sudden and Noise-Induced Sensorineural Hearing Loss; Topline Results Anticipated in Q4 2022 or Q1 2023 Continued Progress on Second Program for Hearing Restoration, FX-345; Phase 1b Start Anticipated in H2 2022 Advances Lead Optimization for Remyelination Program in Multiple Sclerosis ; Selection of Lead Clinical Candidate in 2022; IND Planned in 2023"
01/13/2022 8-K Investor presentation
Docs: "Frequency Therapeutics, Inc. Corporate Slide Presentation as of January 13, 2022",
"Frequency Therapeutics, Inc. Corporate Slide Presentation as of January 13, 2022"
12/10/2021 8-K Quarterly results
12/09/2021 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results Enrollment Underway for FX-322-208 Phase 2b Study in Subjects with Sudden and Noise-Induced Sensorineural Hearing Loss; Aligns with FDA on Speech Perception as Primary Endpoint for FX-322 Studies Expands Pipeline with New Pre-Clinical Program for Hearing Restoration that May Provide Broader Cochlear Exposure and the Potential to Address Expanded SNHL Patient Populations Introduces Remyelination Program in Multiple Sclerosis , Sharing In Vivo Data Showing Substantially Greater Activity than Biologic or Small Molecule Comparators"
11/09/2021 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Frequency Therapeutics, Inc. Corporate Slide Presentation as of November 9, 2021",
"Frequency Therapeutics, Inc. R&D Event Slide Presentation"
10/21/2021 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
09/22/2021 8-K Quarterly results
08/12/2021 8-K Investor presentation, Quarterly results
Docs: "Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results Company Plans to Commence New FX-322 Phase 2 Study in Q4 2021 in a Refined Population of Individuals with Sensorineural Hearing Loss",
"Frequency Therapeutics, Inc. Corporate Slide Presentation as of August 12, 2021"
06/30/2021 8-K Investor presentation
Docs: "Frequency Therapeutics, Inc. Corporate Slide Presentation as of June 30, 2021",
"Frequency Therapeutics, Inc. Corporate Slide Presentation as of June 30, 2021"
06/21/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy